The truth about retinoids: a clinical perspective
By Dr. Cloo Hassan · Founding Dermatologist
Retinoids are the most studied class of medications in dermatology. We have more than sixty years of clinical data, thousands of published trials, and a long catalogue of molecules from simple retinol to oral isotretinoin. And yet, practical application remains opaque to patients and to many physicians.
The first source of confusion: marketing. Nearly every cosmetic brand sells a "retinol" product. Some at concentrations barely worth mentioning, some in formulations that do not survive on the shelf, some with claims that have no basis. This marketing noise confuses even informed patients.
The second source: the complexity of the class itself. Retinoids are not one drug. They are a whole family of molecules that vary in strength, mechanism, and tolerance. Tretinoin, adapalene, tazarotene, trifarotene, isotretinoin, retinol, retinaldehyde. Each has its right place, and each has its wrong place.
What unites these molecules? All act on retinoid receptors in skin cells, modulating cell turnover, stimulating collagen production, regulating sebum, and reducing inflammation. These mechanisms are what make retinoids effective in acne, pigmentation, photoaging, and certain rare conditions.
But mechanism does not mean immediate use of every concentration in every patient. This is where clinical art begins. The first rule: start at the lowest potency and titrate. A patient new to retinoids is best served beginning with 0.2% retinol twice weekly, then doubling frequency every two weeks based on tolerance. Jumping directly to 0.1% tretinoin is a recipe for severe irritation that turns the patient against the entire class.
The second rule: higher concentration does not necessarily mean better result. There is a threshold of effect. Once crossed, raising concentration increases side effects more than it increases benefit. For most cases of photoaging, 0.025% tretinoin does what 0.1% does with much better tolerance.
The third rule: consistency outperforms potency. A patient who uses 0.3% retinol nightly for a year will see far better results than one who uses 0.1% tretinoin and stops after a month due to irritation. Skin requires regular, repeated exposure to change. Histologic changes in collagen occur over months, not days.
The fourth rule: sunscreen is mandatory, not optional. Every patient using retinoids must use a broad-spectrum sunscreen every morning, every day. Retinoids accelerate cellular turnover, which temporarily makes the skin more vulnerable to ultraviolet radiation. Ignoring this step transforms treatment into a pigmentary burden.
In Egyptian and deeper skin tones generally, additional considerations apply. The risk of post-inflammatory hyperpigmentation is high. So we move more slowly, pair retinoids with strong soothing agents such as niacinamide, and avoid combining with other potent acids. How many patients we have received after a colleague prescribed a retinoid plus salicylic acid plus benzoyl peroxide, only to develop inflammation and pigmentation that took months to resolve.
What of oral isotretinoin? This drug changed dermatology. Cases of cystic acne that once required years of treatment and left scars are now permanently resolved in five to eight months. But it is a powerful drug that warrants respect. We select candidates carefully, monitor labs regularly, explain side effects honestly, and do not prescribe it first-line for mild cases.
The summary: retinoids are perhaps the greatest discovery in applied dermatology. But they are a tool, not a magic solution. They deserve respect commensurate with their power. The simplest advice for anyone considering them: do not self-purchase, consult a physician who knows what to prescribe and why. Start slowly. Be patient. And reserve the high concentrations for cases that warrant them.
